Monoclonal Abs to Ab binding domain of MBP

Monoclonal antibodies to a newly identified binding domain on the myelin basic protein were produced in mice and may prevent building interaction, a phenomenon beneficial to Alzheimer's management. Background: Myelin basic protein (MBP) is found in brain myelin and participates in different roles in the maintenance of health and prevention of diseases, namely the myelination of nerves in the central nervous system(CNS). Monoclonal antibodies to a newly identified section of the MBP were created in mice. These antibodies are able to prevent the binding of MBP to amyloid B-protein which is implicated in the development and progression of Alzheimer's disease. Technology Overview: Monoclonal antibodies were generated in mice to a novel region on myelin basic protein, a protein that is abundant in brain myelin and has numerous functions in health and disease. The antibodies have the unique potential to block myelin basic protein binding to amyloid B-protein, a important protein involved in the pathogenesis of Alzheimer's disease. Advantages: Monoclonal antibodies raised to a novel sequence of MBP that are not presently available Applications: Intellectual Property Summary: Stage of Development: Licensing Potential: Licensing Status: Additional Information: Alzheimer's disease, Demyelinating diseases, Dysmyelination, https://stonybrook.technologypublisher.com/files/sites/research-tools-and-reagents1.jpg
Patent Information:
Technology/Start-up ID: